Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019)

Niagen Bioscience (NAGE) has disclosed Amortization of Deferred Charges for 1 consecutive years, with $294000.0 as the latest value for Q3 2019.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $294000.0 in Q3 2019 year-over-year; TTM through Dec 2019 was $846000.0, a N/A change, with the full-year FY2019 number at $846000.0, changed N/A from a year prior.
  • Amortization of Deferred Charges was $294000.0 for Q3 2019 at Niagen Bioscience, down from $414000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $414000.0 in Q2 2019 to a low of $138000.0 in Q1 2019.